|  |
| --- |
| ***Table S4*. Any Grade 2 or Higher Adverse Events Occurring After Initiating Sulindac (n=50)** |
| **Toxicity category1** |  |
|  |  |
| Cardiac disorder | 1 (1.89%) |
| Gastrointestinal disorders\*\* | 8 (15.09%) |
| General disorders and administration site conditions | 8 (15.09%) |
| Hepatobiliary disorders |  |
| Infections and infestations | 7 (13.21%) |
| Injury, poisoning and procedural complications |  |
| Investigations | 1 (1.89%) |
| Metabolism and nutrition disorders | 3 (5.66%) |
| Musculoskeletal and connective tissue disorders | 9 (16.98%) |
| Neoplasms benign, malignant, and unspecified (incl cysts and polyps) | 1 (1.89%) |
| Nervous system disorders | 5 (9.43%) |
| Psychiatric disorders | 3 (5.66%) |
| Reproductive system and breast disorders | 3 (5.66%) |
| Respiratory, thoracic, and mediastinal disorders | 2 (3.77%) |
| Skin and subcutaneous tissue disorders | 3 (5.66%) |
| Surgical and medical procedures | 2 (3.77%) |
| Vascular disorders | 7 (13.21%) |
| **Total number of participants with any AE (grade ≥2)** | **34 (65.4%)** |
| 1If a participant has multiple events within a CTC category, only the highest grade is reported. |